Clinical and Genomic Characteristics of Patients With Advanced NSCLC Who Have Long-Term Response to First-Line Immunotherapy: A Real-World Study.

Introduction: There is a paucity of data about patients with advanced NSCLC (aNSCLC) with disease control for at least 2 years since the start of first-line (1L) immunotherapy. Methods: Databases of five Israeli cancer centers were searched for cases of patients with aNSCLC who commenced 1L treatment with immunotherapy between 2018 and 2021 and had no progression of disease for at least 2 years since treatment initiation. Clinical, pathologic, and genomic sequencing data were retrospectively collected. The end of 2 years from the initiation of treatment was the index date. Progression-free survival (after 2 y) and overall survival (after 2 y) were calculated by Kaplan-Meier method from the index date. Collected variables were examined for correlation with the outcome. Results: A total of 206 patients were included, with a median age of 65 years; 64.1% were males and 6.3% were never-smokers. Brain and liver metastases were found in 22.3% and 4.9%, oligometastatic disease in 80.6%; 62.1% had PDL1 greater than or equal to 50%. Mutations in Conclusions: In real-life settings, aNSCLC (at 2 years or longer) who are responders to 1L immunotherapy have high rates of oligometastatic disease, high PDL1, low rates of never-smoking history, baseline liver metastasis, and